2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Karen A. Hicks(Moffitt Cancer Center), Shari Targum(Center for Drug Evaluation and Research), Roxana Mehran(Mount Sinai Hospital), Biykem Bozkurt(Baylor College of Medicine), Judith H. Lichtman(Yale University), Andrew Farb(Memorial Hermann), Jeffrey P. Jacobs(University of Florida), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Steven E. Nissen(Cleveland Clinic), Donald E. Cutlip(Baim Institute for Clinical Research), Michael R. Jaff(Boston Scientific (United States)), Gregg C. Fonarow(UCLA Medical Center), Bernard Chaitman(Saint Louis University), Marian C. Limacher(Marian University - Indiana), James E. Tcheng(Duke University), Eric E. Smith(University of Calgary)
Cited by 596
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k